Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 16/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 15/20 | 0.60 |
| ▸ | HSP90B1 | P14625 | 6/20 | 0.60 |
| ▸ | TRAP1 | Q12931 | 4/20 | 0.60 |
| ▸ | BCL6 | P41182 | 1/20 | 0.34 |
| ▸ | FASN | P49327 | 2/20 | 0.32 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3634090 | 0.90 | HSP90AB1 (0.73) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL3634084 | 0.90 | HSP90AB1 (0.73) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL3632104 | 0.88 | HSP90AA1 (0.59) | HSP90AB1HSP90AA1HSP90B1TRAP1BCL6 | |
| SCHEMBL3632107 | 0.88 | HSP90AA1 (0.59) | HSP90AB1HSP90AA1HSP90B1TRAP1BCL6 | |
| SCHEMBL3625989 | 0.85 | HSP90AA1 (0.82) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL3625988 | 0.85 | HSP90AA1 (0.82) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL12820977 | 0.81 | HSP90AA1 (0.58) | HSP90AB1HSP90AA1HSP90B1TRAP1BCL6 | |
| SCHEMBL12821044 | 0.81 | HSP90AA1 (0.62) | HSP90AB1HSP90AA1HSP90B1TRAP1BCL6 | |
| SCHEMBL3631673 | 0.79 | HSP90AB1 (0.53) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL8136169 | 0.78 | HSP90AA1 (0.67) | HSP90AB1HSP90AA1HSP90B1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2146967-A2 | TETRAHYDROINDOLE AND TETRAHYDROINDAZOLE DERIVATIVES | Serenex, Inc. (US) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008130879-A2 | TETRAHYDROINDOLE AND TETRAHYDROINDAZOLE DERIVATIVES | SERENEX, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080269193-A1 | Tetrahydroindole and Tetrahydroindazole Derivatives | SERENEX, INC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269193-A1 | Tetrahydroindole and Tetrahydroindazole Derivatives | HSF1, HSP90AB1, TPH1 | HSP90AB1 2/4885HSP90AA1 4/4885HSP90B1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.